Oleg Fedorov
PI, Group Head
- Biochemistry and Biophysics
Molecular Biophysics and Biochemistry group in CMD/TDI Oxford specialises on chemical probe discovery projects, especially in the field of Epigenetics and Ubiquitin system. Main target areas are acetyl-lysine reader domains and E3 ligases. The group supports the wide variety of screening assays developed for most of the targets. The in-depth characterization of drug candidates relies on a series of biophysical techniques established for accurate measurements of thermodynamics of and kinetic parameters of binding. The group also supports and extend the focused libraries of small molecular weight ligands for proteins of interest.
Recent publications
-
Unexpected Noncovalent Off-Target Activity of Clinical BTK Inhibitors Leads to Discovery of a Dual NUDT5/14 Antagonist.
Journal article
Balıkçı E. et al, (2024), J Med Chem, 67, 7245 - 7259
-
Discovery of a Potent, Selective, and Cell-Active SPIN1 Inhibitor.
Journal article
Xiong Y. et al, (2024), J Med Chem, 67, 5837 - 5853
-
Imidazo[1,2-b]pyridazines as inhibitors of DYRK kinases.
Journal article
Henderson SH. et al, (2024), Eur J Med Chem, 269
-
Discovery of PFI-6, a small-molecule chemical probe for the YEATS domain of MLLT1 and MLLT3.
Journal article
Raux B. et al, (2024), Bioorg Med Chem Lett, 98
-
Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors.
Journal article
Boby ML. et al, (2023), Science, 382